{"doi":"10.1016/j.ygyno.2021.06.024","title":"Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors","abstract":null,"journal":"Gynecologic Oncology","year":2021,"id":617388,"datarank":1.0530001276442382,"base_score":3.332204510175204,"endowment":3.332204510175204,"self_citation_contribution":0.49983067652628066,"citation_network_contribution":0.5531694511179577,"self_endowment_contribution":0.49983067652628066,"citer_contribution":0.5531694511179577,"corpus_percentile":null,"corpus_rank":null,"citation_count":27,"citer_count":19,"citers_with_citation_signal":12,"citers_with_endowment":12,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":86393,"name":"Douglas I. Lin","orcid":"0000-0003-0105-9760","position":1,"is_corresponding":false},{"id":1303781,"name":"Barrett Lawson","orcid":null,"position":2,"is_corresponding":false},{"id":328249,"name":"David M. Gershenson","orcid":"0000-0001-9712-2140","position":3,"is_corresponding":false},{"id":459566,"name":"R. Tyler Hillman","orcid":"0000-0002-9832-9925","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors","abstract":"<h4>Objective</h4>The objective of this study was to determine the prevalence of predictive biomarkers associated with FDA-approved therapies in molecularly defined adult-type ovarian granulosa cell tumors (aGCTs).<h4>Methods</h4>We performed a retrospective cross-sectional cohort study of tumor profiles using the inclusion criteria of molecularly defined (FOXL2 c.C402G positive) aGCTs previously sequenced at Foundation Medicine, Inc. The dataset included coding variants for up to 406 genes, microsatellite instability, tumor mutational burden, and genomic loss of heterozygosity (gLOH). PD-L1 expression was determined using the tumor proportion score, as measured using the DAKO 22C3 immunohistochemistry assay.<h4>Results</h4>423 tumor profiles met inclusion criteria. The median age at the time of sample submission was 57 years (interquartile range 48-65). The mean tumor mutational burden was 1.8 mutations per megabase (range 0-8.8). No tumors exhibited microsatellite instability, and none were gLOH-High (≥16%). Sixty-seven tumors had PD-L1 expression measurement, and 94% were negative. Potentially actionable variants including MTAP deletion (12/173, 5.8%) and activating PIK3CA mutations (23/423, 5.4%) were identified. TP53-mutated aGCT had a higher tumor mutational burden (mean 2.4 mut/Mb, 95% CI 1.7-3.0 mut/Mb vs mean 1.7 mut/Mb, 95% CI 1.5-1.9 mut/Mb; P = .02) and higher gLOH score (mean 4.4%, 95% CI 2.7-6.1% vs mean 1.4%, 95% CI 1.2-1.6%; P = .002) than TP53 non-mutated tumors.<h4>Conclusions</h4>No women with molecularly defined aGCT in this large cohort would be eligible for FDA-approved pembrolizumab based on either microsatellite instability or high tumor mutational burden. TP53 mutation identified a subset of this tumor type with distinct molecular features. The development of precision treatment options remains a critical unmet need for this rare disease.","is_dataset_classified":null,"base_score":3.332204510175204,"endowment":3.332204510175204,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34238613","pmcid":"PMC9448642","openalex_id":"https://openalex.org/W3178598818","authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"P30 CA016672","title":null},{"funder_name":"National Institutes of Health","grant_id":"3P30CA016672-41S4","title":"Cancer Center Support (CORE) Grant"}],"total_grants":2,"fwci":2.9375,"citation_percentile":0.9076087,"influential_citations":0,"citation_trend":[{"year":2022,"count":1},{"year":2023,"count":5},{"year":2024,"count":10},{"year":2025,"count":6},{"year":2026,"count":5}],"oa_status":"green","license":"Elsevier TDM","oa_locations":[{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9448642","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/9448642","host_type":"repository"},{"url":"https://api.elsevier.com/content/article/PII:S0090825821005187?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0090825821005187?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.ygyno.2021.06.024","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/34238613","host_type":"repository"},{"url":"https://dx.doi.org/10.1016/j.ygyno.2021.06.024","host_type":""}],"fields_of_study":["Ovarian cancer diagnosis and treatment","PARP inhibition in cancer therapy","Chromatin Remodeling and Cancer","03 medical and health sciences","0302 clinical medicine","Adult","Aged","Biomarkers, Tumor","Cross-Sectional Studies","Female","Forkhead Box Protein L2","Granulosa Cell Tumor","Humans","Immune Checkpoint Inhibitors","Microsatellite Instability","Middle Aged","Mutation","Retrospective Studies","Granulosa cell tumor of the ovary"],"mesh_terms":["Forkhead Box Protein L2","Immune Checkpoint Inhibitors","Adult","Aged","Cross-Sectional Studies","Female","Granulosa Cell Tumor","Humans","Middle Aged","Mutation","Retrospective Studies","Biomarkers, Tumor","Microsatellite Instability"],"keywords":["Medicine","Interquartile range","Cohort","Microsatellite instability","Internal medicine","Oncology","Loss of heterozygosity","Immunohistochemistry","Ovarian cancer","Pathology","Microsatellite","Cancer","Biology","Gene","Genetics","Allele","Immunotherapy","Biomarkers","Granulosa Cell Tumors","Cancergenomics","Adult","Forkhead Box Protein L2","Middle Aged","Cross-Sectional Studies","Mutation","Biomarkers, Tumor","Humans","Female","Immune Checkpoint Inhibitors","Aged","Granulosa Cell Tumor","Retrospective Studies"],"sdg_mappings":[{"sdg_number":3,"sdg_label":"3. Good health"},{"sdg_number":10,"sdg_label":"10. No inequality"},{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-03T01:36:10.831267Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}